Nanocarry develops therapeutics designed to deliver biologics across the Blood-Brain Barrier (BBB) for treating brain cancers and CNS diseases. Their proprietary AXS technology platform enables significantly increased brain delivery of therapeutic antibodies using a Plug & Play approach. This platform facilitates the creation of novel biologics to address neurological conditions currently excluded by existing treatments.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The blood-brain barrier (BBB) restricts the passage of most therapeutic biologics, including antibodies, into the brain, limiting treatment options for brain cancers and central nervous system (CNS) diseases. Less than 0.01% of an injected dose of therapeutic antibodies reaches the brain, leaving a significant unmet need for effective CNS-targeted therapies.
Solution
Nanocarry is developing a nanoparticle-based AXS technology platform designed to enhance the delivery of biologics across the blood-brain barrier. This platform utilizes a "Plug & Play" approach to increase the brain uptake of therapeutic antibodies, achieving up to a 50-fold increase in delivery with 8x the payload compared to traditional methods. By overcoming the BBB, Nanocarry aims to enable targeted therapies for brain metastases of breast and lung cancers, neurodegenerative diseases, and genetic diseases of the CNS. The AXS platform facilitates the creation of novel therapeutics with optimized modalities and mechanisms of action.
Target Audience
The primary target audience includes patients with brain cancers and central nervous system diseases, as well as pharmaceutical companies seeking to co-develop next-generation therapeutics for neurodegenerative and genetic diseases of the CNS.
Features
- Proprietary AXS technology platform for enhanced delivery of biologics across the blood-brain barrier
- Nanoparticle-based therapeutics to increase brain uptake of therapeutic antibodies
- "Plug & Play" approach for creating novel therapeutics with optimal modalities and mechanisms of action
- Demonstrated up to 50-fold increase in brain delivery of antibody’s injected dose
- Capable of delivering 8x the payload compared to traditional methods
- Developing an in-house neuro-oncology pipeline for brain metastases of breast and lung cancers